Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2009

Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association
Scientific Sessions 2009
Cardiometabolic and genetic testing complement advanced cholesterol profile

BIRMINGHAM, Ala., Oct. 29 /PRNewswire/ -- Atherotech, Inc., a cardiodiagnostic
company, announced it will exhibit its VAP® Cholesterol Test at the American
Heart Association Scientific Sessions 2009. The annual meeting takes place
November 14-18 at the Orange County Convention Center in Orlando, Fla.

Representatives for Atherotech will be available during regular exhibit hours
on November 15, 16 and 17 to discuss the VAP Cholesterol Test in booth No.
1814, and the VAP Test will be provided via blood draw to qualified attendees.
Because LDL is directly measured, fasting is not required. Test results will
be returned via mail after the conference.

The VAP (Vertical Auto Profile) Test, an expanded cholesterol profile that
directly measures the content of all lipids, identifies a far greater number
of people at risk for heart disease than standard cholesterol tests.

"Attendees will learn how we're complementing our VAP Test offering with the
addition of cardiometabolic and genetic testing, giving physicians and
cardiology practices a single source for multiple test panels," said
Atherotech Chief Medical Officer Michael E. Cobble, M.D.

The VAP Test reports 20 separate components of cholesterol, and unlike other
lipid profiles, it directly measures all three lipoprotein parameters -- LDL,
non-HDL and apoB -- considered necessary by the expert consensus guidelines
issued by the American Diabetes Association and American College of
Cardiology. The VAP Test is also the only single cholesterol test that
routinely reports apoAI, apoB and the apoB/apoAI ratio.

Atherotech continues to grow its cardiodiagnostic business. The company
recently added the PLAC Test for identification of increased heart attack and
stroke risk and the cystatin C test as an early, sensitive marker for chronic
kidney disease. Unlike creatinine, cystatin C is not affected by muscle mass,
gender, age or race. Cystatin C has been shown to be a superior marker of
kidney function compared to creatinine, according to the National Kidney
Foundation.

Other cardiometabolic and genetic tests now available through Atherotech
include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, creatinine,
creatine kinase (CK), HbA1c, insulin, TSH, ALT, AST, urea nitrogen (BUN),
glucose, vitamin D and homocysteine. Cardiometabolic test panels can be
ordered individually or bundled as part of a custom risk profile that also
includes the advanced VAP Cholesterol Test.

People with a family history or an existing condition of diabetes, high blood
pressure or heart disease -- or who are already taking cholesterol-lowering
medication -- are candidates for the VAP Test.

The VAP Test is available nationwide. For more information call 877.901.8510
or visit www.thevaptest.com.

About Atherotech, Inc.
Atherotech is a CLIA-certified clinical reference laboratory and
cardiodiagnostic company focusing on cardiometabolic tests, including the
company's patented VAP Cholesterol Test, which reports the cholesterol content
of all lipids, components and subclasses. The VAP Test is the first
cholesterol profile to comply with updated National Cholesterol Education
Program ATP III recommendations for direct LDL measurement, which is accurate
with non-fasting samples. It is the only advanced lipid profile that routinely
reports all three lipoprotein parameters considered necessary by the American
Diabetes Association and American College of Cardiology expert consensus
guidelines. The VAP Test is available through national and regional diagnostic
laboratories and is reimbursed by many of the largest private insurers as well
as Medicare. For more information, visit www.thevaptest.com.

SOURCE Atherotech, Inc.

Dan Snyders of Armada Medical Marketing, +1-303-623-1190, ext. 230,
dan@armadamedical.com, for Atherotech, Inc.; or Scott Rezek of Atherotech,
Inc., +1-205-314-7412, srezek@atherotech.com